期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Clinical significance of extended high-risk human papillomavirus genotyping and viral load in cervical cancer and precancerous lesions 被引量:2
1
作者 Pingping Su Jincheng Ma +2 位作者 Lirui Yu Shuting Tang Pengming Sun 《Gynecology and Obstetrics Clinical Medicine》 2023年第1期22-29,共8页
Persistent infections with specific high-risk human papillomavirus(HR-HPV)strains are the leading cause of cervical cancer and precancerous lesions.HPV-16 and HPV-18 are associated with more than 70%of cervical cancer... Persistent infections with specific high-risk human papillomavirus(HR-HPV)strains are the leading cause of cervical cancer and precancerous lesions.HPV-16 and HPV-18 are associated with more than 70%of cervical cancer.However,with recent widespread vaccination efforts against cervical cancer,the infection rates of HPV-16 and HPV-18 have decreased across all age groups,while the infection rates of other HR-HPV strains have increased.The non-16/18 HR-HPV strains play an important role in cervical lesions.These strains can be identified with extended genotyping,and the 2019 American Society for Colposcopy and Cervical Pathology(ASCCP)guidelines recommended an HPV-based testing to assess the risk of cervical disease in patients.We reviewed and analyzed the clinical benefits of applying extended HR-HPV genotyping,which was published by the International Agency for Research on Cancer(HPV-16,18,31,33,35,39,45,51,52,56,58,59,66,and 68),to cervical cancer screening.This review concluded that cervical cancer screening needs to include extended HR-HPV genotyping.The examination of extended HR-HPV genotyping in cervical intraepithelial lesions and cervical cancers can help guide clinical practices. 展开更多
关键词 high-risk human papillomavirus Cervical cancer GENOTYPE Viral load Cancer screening
原文传递
Evaluation of dry specimen transport and processing time using an isothermal amplification high-risk human papillomavirus assay
2
作者 Longhua Hu Suhui Wu +5 位作者 Haixia Shang Jerome Belinson Jinhong Li Xiaoqin Wu Yaling Huang Jingfen Sun 《Gynecology and Obstetrics Clinical Medicine》 2022年第1期34-37,共4页
Background:Dry specimen transport has shown equivalence to traditional liquid transport using a novel high-risk Human papillomavirus assay.Considering that dry transport might cross obstacles during cervical cancer sc... Background:Dry specimen transport has shown equivalence to traditional liquid transport using a novel high-risk Human papillomavirus assay.Considering that dry transport might cross obstacles during cervical cancer screening in low and middle resource settings,this study was designed evaluate different processing time of dry specimen transport using the same isothermal amplification hrHPV assay.Methods:There were 564 women between the ages of 30–55 recruited from colposcopy clinic.For each patient,two endocervical samples were collected and placed into empty collection tubes by physician.Samples were stored at room temperature until analyzed for hrHPV using the AmpFire assay at two time points:2 days and 2 weeks.511 of the 564 participants with positive hrHPV were provided colposcopy exam and quadrant biopsy.Results:A total of 1128 endocervical samples from 564 patients were detected by the Ampfire assay.Good agreement was found between two time periods(KappaStandard error=0.67±0.04).Sensitivity(2days/2weeks)for CIN2t was 95.28%(95%CI:92.14%–98.42%)vs 90.57%(CI(86.65%–94.49%)and specificity(2days/2weeks)was 22.47%(CI 19.33%–25.61%)vs 28.15%(CI 24.23%–32.07%)respectively.The difference for Ampfire HPV detection in sensitivity for CIN2t for the two time periods was not significant(P=0.227),while the difference in specificity for CIN2t was significant(P=0.001).The difference in Ct values 29.23(CI 28.15–30.31)and 29.27(CI 28.19–30.35)between two time points was not significant(P?0.164).Conclusion:Processing dry brush specimens can be delayed up to 2 weeks.Using the AmpFire assay platform which supports cervical cancer prevention programs in low-to-middle-income countries(LMICs). 展开更多
关键词 Cervical cancer SCREENING high-risk human papillomavirus Specimen transport Processing time Sample preparation
原文传递
Efficacy of 2LPAPI®, a Micro-Immunotherapy Drug, in Patients with High-Risk Papillomavirus Genital Infection
3
作者 Gilles Thomas Hélène Cluzel +2 位作者 Jacqueline Lafon Jacques Bruhwyler Béatrice Lejeune 《Advances in Infectious Diseases》 2016年第1期7-14,共8页
Human papillomaviruses (HPVs) are well known for being linked to the development of cervical cancers, most of them being caused by the high-risk (HR) oncogenic genotypes, mainly 16 and 18. The efficacy of 2LPAPI<su... Human papillomaviruses (HPVs) are well known for being linked to the development of cervical cancers, most of them being caused by the high-risk (HR) oncogenic genotypes, mainly 16 and 18. The efficacy of 2LPAPI<sup><sup>&reg;</sup> </sup>(Labo’Life), a micro-immunotherapy homeopathic drug, has been evaluated in HR-HPV infected women (n = 18), in a private gynecology practice, by comparing them to an untreated control group (n = 18). Patients were 20 to 45 years old and had cytology with Atypical Squamous Cells of Undetermined Significance (ASCUS) or Low grade Superficial Intra Lesions/ Cervical Intraepithelial Neoplasia Grade I (LSIL/CINI). Patients freely chose to be treated with the drug or not. Those deciding not to take the drug remained untreated and were followed as a control group. The drug was taken at the regimen of one capsule per day during 6 months. HR-HPV and cytology were evaluated at 6 and 12 months. After 12 months, HR-HPV was cleared in 78% of the patients taking the drug versus 44% in those not taking it (p = 0.086). In patients over 25 years, HR-HPV clearance in the treated group was significantly higher (81.3%) than in the control group (20%) (p = 0.004). The difference in the regression of the lesion grades almost reached statistical significance (p = 0.053). This follow-up confirms that the micro-immunotherapy drug 2LPAPI<sup><sup>&reg;</sup></sup> is a safe and effective therapeutic approach to treat HR-HPV cervical lesions in women over 25 years. 展开更多
关键词 high-risk human papillomavirus Micro-Immunotherapy Genital Infection HOMEOPATHY 2LPAPI®
下载PDF
高危型HPV在宫颈癌发生中的作用 被引量:5
4
作者 刘水平 蒋海鹰 +2 位作者 郑晖 颜亚晖 冯德云 《实用预防医学》 CAS 2005年第5期1023-1024,共2页
本文利用PCR技术检测了44例宫颈癌患者和15例慢性宫颈炎患者病变组织中高危型HPV(16,18,31,33)的感染率,发现44例宫颈癌患者高危型HPV的阳性率高达91%(40/44),其中HPV16型感染率54.55%(24/44),HPV18型感染率18.2%(8/44),HPV31型感染率13... 本文利用PCR技术检测了44例宫颈癌患者和15例慢性宫颈炎患者病变组织中高危型HPV(16,18,31,33)的感染率,发现44例宫颈癌患者高危型HPV的阳性率高达91%(40/44),其中HPV16型感染率54.55%(24/44),HPV18型感染率18.2%(8/44),HPV31型感染率13.6%(6/44),HPV33型感染率4.55%(2/44);15例慢性宫颈炎患者有2例感染HPV16型。结果提示HPV16型是宫颈癌发生最常见的基因型,其次为HPV18型和HPV31型,故对育龄妇女定期进行高危型HPV感染的普查,在早期预防宫颈癌的发生具有十分重要的意义;联合采用分子生物学和宫颈脱落细胞学技术进行即定期普查,既能提高阳性率,又能对感染高危型HPV的慢性宫颈炎患者进行早期的有效预防。 展开更多
关键词 宫颈癌 人类乳头状瘤病毒 多聚酶链式反应
下载PDF
Correlation of HPV infection with TLRs pathway activation and downstream gene expression in cervical precancerous lesions
5
作者 Bilikezi·aikemu Wei Gong +1 位作者 Bahargul·ismawyil Ming-Ming Yue 《Journal of Hainan Medical University》 2018年第12期63-66,共4页
Objective: To study the correlation of HPV infection with TLRs pathway activation and downstream gene expression in cervical precancerous lesions. Methods: Cervical precancerous lesion tissues from surgical resection ... Objective: To study the correlation of HPV infection with TLRs pathway activation and downstream gene expression in cervical precancerous lesions. Methods: Cervical precancerous lesion tissues from surgical resection or cone biopsy in Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University between June 2014 and May 2017 were collected and divided into HR-HPV positive group and HR-HPV negative group according to the condition of high-risk HPV infection;normal cervical tissues surgically removed due to fibroid in Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University during the same period were collected as the control group. The contents of TLRs pathway molecules as well as the expression of apoptosis-related genes and invasion-related genes in the cervical precancerous lesion tissues and normal cervical tissues were determined. Results:TLR2, TLR3, TLR4, TLR9 and NF-κB contents as well as CyclinD1, PCNA, iNOS, Gal-9, N-cadherin, HIF-1α and VEGF mRNA expression in HR-HPV positive group and HR-HPV negative group were significantly higher than those in control group whereas p53, Beclin1, LC3-II and SFRP2 mRNA expression were significantly lower than those in control group, and TLR2, TLR3, TLR4, TLR9 and NF-κB contents as well as CyclinD1, PCNA, iNOS, Gal-9, N-cadherin, HIF-1α and VEGF mRNA expression in HR-HPV positive group were significantly higher than those in HR-HPV negative group whereas p53, Beclin1, LC3-II and SFRP2 mRNA expression were significantly lower than those in HR-HPV negative group. Conclusion: HPV infection in cervical precancerous lesions can regulate downstream apoptosis and invasion gene expression by activating multiple TLRs pathways. 展开更多
关键词 Cervical cancer Precancerous lesion high-risk human papillomavirus Toll-like receptor
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部